Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

BACKGROUND: Estrogen receptor (ER) positive breast cancer is often effectively treated with drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). However, 30% of ER+ breast cancer patients develop resistance to therapy leading to tumour recurrence. Changes in the met...

Descripción completa

Detalles Bibliográficos
Autores principales: Soleimani Dodaran, Maryam, Borgoni, Simone, Sofyalı, Emre, Verschure, Pernette J., Wiemann, Stefan, Moerland, Perry D., van Kampen, Antoine H. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368985/
https://www.ncbi.nlm.nih.gov/pubmed/32684154
http://dx.doi.org/10.1186/s12885-020-07100-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368985/
https://www.ncbi.nlm.nih.gov/pubmed/32684154
http://dx.doi.org/10.1186/s12885-020-07100-z

Ejemplares similares